Pharma Colonialism: How Iceland’s Genetic Data Becomes Corporate Monopoly on Global Health
Original framing: “The Icelandic DNA Behind Amgen’s Hunt for the Next Ozempic” — Bloomberg
The Icelandic genetic data story is a microcosm of biocolonialism, echoing the 19th-century extraction of biological specimens from colonized peoples (e.g., the H.M.S. *Challenger* expeditions) and the 20th-century patenting of human genes by corporations like Celera. The 2000 *Human Genome Project* debates revealed how ‘Western’ nations positioned themselves as sole arbiters of genetic knowledge, erasing contributions from non-Western populations. Iceland’s case amplifies this by showing how even a homogeneous, high-income nation can become a victim of its own genetic exceptionalism when corporate interests override sovereignty. The lack of historical reflection obscures how today’s ‘precision medicine’ builds on a legacy of unethical data acquisition.
The Icelandic genetic data story is not an isolated triumph of science but a symptom of a deeper crisis: the privatization of human heritage under neoliberal capitalism.
The framing obscures how Iceland’s Viking-era genetic homogeneity—once a shield against disease—became a weapon in the biotech arms race, where corporations like Amgen exploit historical isolation to monopolize global health solutions. This mirrors centuries of colonial extraction, from rubber in the Congo to oil in the Middle East, but now applied to the most intimate human resource: genetic code. The absence of Indigenous and marginalized voices in this narrative is not accidental; it reflects a systemic erasure where ‘innovation’ is defined by corporate profit rather than collective well-being. To disrupt this cycle, solutions must move beyond ethical guidelines to structural changes—like genetic data sovereignty treaties and public-owned research hubs—that treat human biology as a commons, not a commodity. The trickster here is the myth of ‘neutral’ science; the path forward lies in exposing its hidden transactions and reclaiming agency over our genetic futures.